Back to Search Start Over

Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes.

Authors :
Norström MM
Rådestad E
Sundberg B
Mattsson J
Henningsohn L
Levitsky V
Uhlin M
Source :
Oncotarget [Oncotarget] 2016 Apr 26; Vol. 7 (17), pp. 23581-93.
Publication Year :
2016

Abstract

Benign prostatic hyperplasia (BPH) is a common chronic non-malignant condition whose prevalence substantially increases with age. Immune cell infiltration and pro-inflammatory mediators have been implicated in the pathogenesis. Here, we characterized 21 extracellular markers on prostate-infiltrating lymphocytes (PILs) and analyzed expression of 26 soluble proteins in prostate tissue obtained from BPH patients (n = 31). These data were correlated with clinical parameters and compared with peripheral blood mononuclear cells (PBMCs) (n = 10). Increased frequencies of T cells expressing co-inhibitory receptors LAG-3, PD-1, TIM-3 or CTLA-4, and co-stimulatory receptors CD28, OX40 or 4-1BB were observed in BPH tissue compared to PBMCs. These findings are consistent with chronic activation and possible functional exhaustion of PILs that may be further augmented by several identified pro-inflammatory factors, such as IL-8 and MCP-1, promoting inflammation and chemotaxis of immune cells to the prostate. Prostate size and plasma prostate-specific antigen levels positively correlated with IL-8 and MCP-1 concentrations, and frequencies of T cells expressing CTLA-4 and TIM-3. It remains to be established whether the link between inflammation and BPH progression supported by our findings reflects a progressive failure of the immune system leading to decreased immune surveillance and development of prostate cancer.<br />Competing Interests: The authors declare there are no conflicts of interest in regards to the present study.

Details

Language :
English
ISSN :
1949-2553
Volume :
7
Issue :
17
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
26993768
Full Text :
https://doi.org/10.18632/oncotarget.8051